UBS raised the firm’s price target on Kymera Therapeutics (KYMR) to $90 from $70 and keeps a Buy rating on the shares. The firm previews December Phase 1b data for KT-621 in atopic dermatitis, expecting strong biomarker and early clinical responses similar to dupilumab along with clean safety, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics announces first patient dosed in BROADEN2 Phase 2b trial
- Kymera Therapeutics management to meet with Truist
- Kymera Therapeutics price target raised to $84 from $70 at H.C. Wainwright
- Kymera Therapeutics price target raised to $70 from $60 at Barclays
- Kymera Therapeutics Reports Q3 2025 Financial Results